REGN : Summary for Regeneron Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 8 hrs 15 mins

Regeneron Pharmaceuticals, Inc. (REGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
369.15+7.14 (+1.97%)
At close: 4:00 PM EST
People also watch:
ALXNBIIBCELGVRTXBMRN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close362.01
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range359.50 - 370.32
52 Week Range325.35 - 563.79
Volume965,198
Avg. Volume863,992
Market Cap39.61B
Beta1.54
PE Ratio (TTM)53.86
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key
    Investor's Business Daily8 hours ago

    Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key

    Biotech stocks have nearly "round-tripped" their Donald Trump-inspired rally.

  • Investopedia10 hours ago

    EU Regulators Will Review Regeneron's Eczema Drug

    Regeneron and Sanofi’s eczema drug makes progress toward being marketed in Europe.

  • Reuters23 hours ago

    EU regulator accepts Sanofi/Regeneron's Dupixent product for review

    The European Medicines Agency (EMA), the European Union's health regulator, has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron, the companies said on Thursday. Dupixent is aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. If cleared by regulators, Dupixent would be the first approved systemic treatment for eczema, which in severe cases produces infection-prone rashes and a constant itch as bad as poison ivy.